Your Messages Inbox
Your Article Summary
See Latest ArticlesMedImmune Expands Access for Eligible Premature Infants to Receive Synagis(R) at No Cost
Medimmune, 06/30/09
MedImmune announced the expansion of the MedImmune Assistance Program for Synagis designed to provide the antibody at no cost to qualifying patients who lack health insurance and whose family household income falls within a certain range of the Federal Poverty Level guidelines established by the U.S. Department of Health and Human Services. Synagis is a biologic medicine known as a monoclonal antibody administered monthly to high-risk infants to prevent serious lower respiratory tract infection caused by respiratory syncytial virus, a leading cause of viral respiratory infection among infants.
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
A flexible operational unit simplifies the use of disposable equipment and ushers in a new level of biomanufacturing
b3c newswire, 12/02/09
Complete Genomics and GATC Biotech Collaborate on Human Genome Sequencing Projects
b3c newswire, 12/02/09
GSK Update: GSKs Arepanrix? H1N1 pandemic vaccine prequalified by the World Health Organization
GlaxoSmithKline, 12/02/09
Article Search
Sponsor